www.modernatx.com
Open in
urlscan Pro
108.138.17.95
Public Scan
Submitted URL: https://i.modernatx.com/OTQ5LUJERy0yNzQAAAGMyxLTqCz-tG70TNk7zAVg280QHAEbZ6y5SuDRm8x8GxcX7UjNjg1nTzNpqOkK6n6_8XrOhlg=
Effective URL: https://www.modernatx.com/?tc=em_5rtj0d2&cc=4013&mkt_tok=OTQ5LUJERy0yNzQAAAGMyxLTqIIZKi8BdlF1Ao_EAYM3k3Qe6c3KlNX9cxKiAE3g-...
Submission: On July 06 via api from US — Scanned from DE
Effective URL: https://www.modernatx.com/?tc=em_5rtj0d2&cc=4013&mkt_tok=OTQ5LUJERy0yNzQAAAGMyxLTqIIZKi8BdlF1Ao_EAYM3k3Qe6c3KlNX9cxKiAE3g-...
Submission: On July 06 via api from US — Scanned from DE
Form analysis
0 forms found in the DOMText Content
Skip to main content * mRNA pipeline * Careers * Newsroom * Blogs * | * Health Care Professionals * Investors * Clinical trials * About Us * The Power of mRNA * Research * Responsibility * COVID-19 USA English Search LANGUAGE OPTIONS United States English LOOKING FOR ANOTHER LOCATION? ASIA PACIFIC Australia English Japan 日本 Hong Kong 中文 South Korea 한국어 Taiwan 中文 EUROPE France Français Germany Deutsch Italy Italiano Netherlands Nederlands Spain Español Switzerland Deutsch Français Italiano United Kingdom English NORTH AMERICA Canada English Français United States English SOUTH AMERICA LATAM Español LATAM Português IMPACTING HUMAN HEALTH: REFLECTING ON OUR ESG PROGRESS Read Shannon Thyme Klinger's blog post 1/2 NewsJob opportunitiesBlogs Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345 05 July 2023 Moderna Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine 03 July 2023 Taking Action and Raising Awareness: The Impact of Cytomegalovirus (CMV) 28 June 2023 Moderna Files for FDA Authorization of Its Updated COVID-19 Vaccine 22 June 2023 Impacting Human Health: Reflecting on our ESG Progress 14 June 2023 Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA 05 June 2023 View all news 12 Years of progress 48 Products in pipeline 35 Ongoing clinical trials MEET MODERNA Moderna’s goal is to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients. See our mission JOIN US AND CHANGE THE WORLD OF MEDICINE Life at Moderna SO, WHAT IS MRNA? Messenger RNA (mRNA) already exists in your body. It carries a “message” - instructions that direct your cells what to do. Fighting disease differentlyLimitless treatmentsHelping more peopleMore medicines, faster FIGHTING DISEASE DIFFERENTLY mRNA medicines fight diseases in a different way than traditional medicine by prompting your immune system to create the tools to treat or prevent disease. Learn more about mRNA LIMITLESS TREATMENTS We believe that if mRNA can treat one disease, it can treat many diseases. We will use mRNA to treat diseases for which there are currently no treatments. Learn more about mRNA HELPING MORE PEOPLE mRNA medicine contains no animal products or preservatives, making medicine accessible for as many people as possible. Learn more about mRNA MORE MEDICINES, FASTER Our platform enables rapid design, research and testing of multiple mRNAs, within days. Our novel production methods allow us to get medicines to more people, faster. Learn more about mRNA 1/4 MEET HAMILTON SENIOR DIRECTOR, VACCINE ACCESS AND PARTNERSHIPS It normally takes 10-15 years to develop a vaccine. With the COVID-19 pandemic, Hamilton knew she didn’t have years – she led her team from development and into early trials within two months. Meet more team members POPULAR MEDIA More media See Moderna’s Ad from the 2022 US Open Video 25 August 2022 Questions & Answers with Rose Loughlin Blog 11 February 2022 The Future of Vaccines with Moderna CEO Stéphane Bancel Podcast 25 October 2021 Moderna and Flagship Pioneering: Noubar Afeyan Podcast 11 October 2021 2022 ESG REPORT Our journey to building the best version of Moderna Click here to read our 2022 report INVESTORS * Investors overview NEWSROOM * News and media * Media kit PATENTS * Patents MEDIA CENTER * All media * Blogs * Videos * Podcasts PARTNERSHIPS * Strategic collaborators CAREERS * Life at Moderna * People behind the science * Awards * Join our team INNOVATION INCUBATOR * New Venture Labs * Terms of use * Privacy statement * Contact Moderna * Sitemap © 2023 Moderna, Inc. We collect cookies This website stores data such as cookies to enable essential site functionality, as well as marketing, personalization, and performance. Privacy Statement * Strictly Necessary These items are required to enable basic website functionality. * Marketing These items are used to deliver advertising that is more relevant to you and your interests. They may also be used to limit the number of times you see an advertisement and measure the effectiveness of advertising campaigns. Advertising networks usually place them with the website operator’s permission. * Personalization These items allow the website to remember choices you make (such as your user name, language, or the region you are in) and provide enhanced, more personal features. For example, a website may provide you with local weather reports or traffic news by storing data about your current location. * Performance These items help the website operator understand how its website performs, how visitors interact with the site, and whether there may be technical issues. This storage type usually doesn’t collect information that identifies a visitor. Show Details Show Less Deny Accept All